327092-81-9

Basic information

• Product Name: 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid
• Synonyms: 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid;3-((3,4-Dihydroisoquinolin-2(1H)-yl)sulfonyl)benzoic acid;3-(3,4-dihydro-1H-isoquinolin-2-ylsulfonyl)benzoic acid;BAS 05946210;Benzoic acid, 3-(3,4-dihydro-1H-isoquinoline-2-sulfonyl)-;EU-0040696;Oprea1_065304;TimTec1_006094
• CAS NO: 327092-81-9
• Molecular Formula: C₁₆H₁₅NO₄S
• Molecular Weight: 317
• Mol File: 327092-81-9.mol

Chemical Properties

• Boiling Point: 555.1±60.0 °C(Predicted)
• Appearance: /
• Density: 1.397±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.72±0.10(Predicted)
• CAS DataBase Reference: 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid(327092-81-9)
• EPA Substance Registry System: 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid(327092-81-9)

Safety Data

• Hazardous Substances Data: 327092-81-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid is used as a potential pharmaceutical candidate for various applications due to its unique structural features and functional groups. Its dihydroisoquinoline ring system and sulphonamide group may contribute to its biological activities and therapeutic potential.
Used in Drug Discovery and Development:
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid is used as a starting material or a scaffold in drug discovery and development processes. Its structural features and functional groups can be further modified or optimized to enhance its biological activities and therapeutic properties.
Used in Medicinal Chemistry Research:
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid is used as a subject of study in medicinal chemistry research to explore its potential as a lead compound for the development of new drugs. Researchers may investigate its interactions with biological targets, its pharmacokinetic properties, and its safety and efficacy profiles.
Note: The specific applications and reasons for using 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulphonyl)benzoic acid may vary depending on the research context and the identified biological activities. The provided uses are general and based on the information given in the materials. Further research is necessary to fully understand its potential applications and therapeutic uses.

Upstream product

• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 4025-64-3 3-Carboxybenzenesulfonyl chloride 

Downstream Products

• 893761-44-9 C₁₆H₁₄ClNO₃S 
• 915895-30-6 C₂₀H₂₂N₂O₄S 
• 1394241-80-5 C₂₀H₂₂N₂O₃S₂ 
• 1394241-81-6 C₂₀H₂₅N₃O₃S 
• 445227-19-0 C₁₇H₁₈N₂O₃S 
• 1327484-39-8 C₁₈H₂₀N₂O₃S 

Relevant articles and documents

3-(3,4-dihydroisoquinolin-2(1 H)-ylsulfonyl)benzoic acids: Highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3

A high-throughput screen identified 3-(3,4-dihydroisoquinolin-2(1H)- ylsulfonyl)benzoic acid as a novel, highly potent (low nM), and isoform-selective (1500-fold) inhibitor of aldo-keto reductase AKR1C3: a target of interest in both breast and prostate cancer. Crystal structure studies showed that the carboxylate group occupies the oxyanion hole in the enzyme, while the sulfonamide provides the correct twist to allow the dihydroisoquinoline to bind in an adjacent hydrophobic pocket. SAR studies around this lead showed that the positioning of the carboxylate was critical, although it could be substituted by acid isosteres and amides. Small substituents on the dihydroisoquinoline gave improvements in potency. A set of reverse sulfonamides showed a 12-fold preference for the R stereoisomer. The compounds showed good cellular potency, as measured by inhibition of AKR1C3 metabolism of a known dinitrobenzamide substrate, with a broad rank order between enzymic and cellular activity, but amide analogues were more effective than predicted by the cellular assay.

Discovery of a novel class of PPARδ partial agonists

Anthranilic acid GW9371 was identified as a novel class of PPARδ partial agonist through high-throughput screening. The design and synthesis of SAR analogues is described. GSK1115 and GSK7227 show potent partial agonism of the PPARδ target genes CPT1a and PDK4 in skeletal muscle cells.